CARL ZEISS MEDITEC AG - BR (AFX.DE) Fundamental Analysis & Valuation
FRA:AFX • DE0005313704
Current stock price
27.73 EUR
-0.11 (-0.4%)
Last:
This AFX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AFX.DE Profitability Analysis
1.1 Basic Checks
- In the past year AFX was profitable.
- AFX had a positive operating cash flow in the past year.
- AFX had positive earnings in each of the past 5 years.
- In the past 5 years AFX always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of AFX (4.15%) is better than 62.30% of its industry peers.
- The Return On Equity of AFX (6.67%) is comparable to the rest of the industry.
- AFX has a Return On Invested Capital of 5.79%. This is comparable to the rest of the industry: AFX outperforms 52.46% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AFX is below the industry average of 10.31%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
- The Profit Margin of AFX (6.34%) is comparable to the rest of the industry.
- In the last couple of years the Profit Margin of AFX has declined.
- The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
- AFX's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 52.76%, AFX is doing worse than 62.30% of the companies in the same industry.
- AFX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. AFX.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
- AFX has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for AFX has been reduced compared to 5 years ago.
- AFX has a better debt/assets ratio than last year.
2.2 Solvency
- AFX has an Altman-Z score of 2.94. This is not the best score and indicates that AFX is in the grey zone with still only limited risk for bankruptcy at the moment.
- AFX has a Altman-Z score (2.94) which is comparable to the rest of the industry.
- AFX has a debt to FCF ratio of 4.41. This is a neutral value as AFX would need 4.41 years to pay back of all of its debts.
- AFX has a Debt to FCF ratio (4.41) which is comparable to the rest of the industry.
- AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
- AFX's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. AFX outperforms 55.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 2.94 |
ROIC/WACC0.86
WACC6.72%
2.3 Liquidity
- AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
- AFX's Current ratio of 2.35 is fine compared to the rest of the industry. AFX outperforms 62.30% of its industry peers.
- A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
- The Quick ratio of AFX (1.44) is better than 63.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. AFX.DE Growth Analysis
3.1 Past
- AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.51%.
- AFX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.28% yearly.
- The Revenue has been growing slightly by 5.89% in the past year.
- The Revenue has been growing by 10.78% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
3.2 Future
- The Earnings Per Share is expected to grow by 14.94% on average over the next years. This is quite good.
- AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.17% yearly.
EPS Next Y-11.59%
EPS Next 2Y7.85%
EPS Next 3Y11.93%
EPS Next 5Y14.94%
Revenue Next Year0.72%
Revenue Next 2Y3.1%
Revenue Next 3Y4.03%
Revenue Next 5Y5.17%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. AFX.DE Valuation Analysis
4.1 Price/Earnings Ratio
- AFX is valuated rather expensively with a Price/Earnings ratio of 18.99.
- Compared to the rest of the industry, the Price/Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 77.05% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of AFX to the average of the S&P500 Index (27.89), we can say AFX is valued slightly cheaper.
- A Price/Forward Earnings ratio of 14.81 indicates a correct valuation of AFX.
- AFX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AFX is cheaper than 75.41% of the companies in the same industry.
- AFX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.50.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.99 | ||
| Fwd PE | 14.81 |
4.2 Price Multiples
- AFX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. AFX is cheaper than 86.89% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than 78.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.61 | ||
| EV/EBITDA | 8.58 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)5.79
EPS Next 2Y7.85%
EPS Next 3Y11.93%
5. AFX.DE Dividend Analysis
5.1 Amount
- With a Yearly Dividend Yield of 1.98%, AFX has a reasonable but not impressive dividend return.
- In the last 3 months the price of AFX has falen by -29.41%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- Compared to an average industry Dividend Yield of 1.26, AFX pays a bit more dividend than its industry peers.
- Compared to an average S&P500 Dividend Yield of 1.82, AFX has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.98% |
5.2 History
- The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
- AFX pays out 37.19% of its income as dividend. This is a sustainable payout ratio.
DP37.19%
EPS Next 2Y7.85%
EPS Next 3Y11.93%
AFX.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:AFX (4/20/2026, 3:31:41 PM)
27.73
-0.11 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12 2026-02-12/dmh
Earnings (Next)05-12 2026-05-12
Inst Owners23.27%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.48B
Revenue(TTM)2.20B
Net Income(TTM)141.22M
Analysts66.09
Price Target34.74 (25.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.98% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)-30.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30.35%
EPS NY rev (1m)-12.68%
EPS NY rev (3m)-28.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)-1.45%
Revenue NY rev (3m)-3.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.99 | ||
| Fwd PE | 14.81 | ||
| P/S | 1.11 | ||
| P/FCF | 18.61 | ||
| P/OCF | 11.82 | ||
| P/B | 1.17 | ||
| P/tB | 5.13 | ||
| EV/EBITDA | 8.58 |
EPS(TTM)1.46
EY5.27%
EPS(NY)1.87
Fwd EY6.75%
FCF(TTM)1.49
FCFY5.37%
OCF(TTM)2.35
OCFY8.46%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)N/A
PEG (5Y)5.79
Graham Number27.8812 (0.55%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 2.94 |
F-Score6
WACC6.72%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.51%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-83.33%
EPS Next Y-11.59%
EPS Next 2Y7.85%
EPS Next 3Y11.93%
EPS Next 5Y14.94%
Revenue 1Y (TTM)5.89%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%-4.79%
Revenue Next Year0.72%
Revenue Next 2Y3.1%
Revenue Next 3Y4.03%
Revenue Next 5Y5.17%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year39.7%
EBIT Next 3Y21.85%
EBIT Next 5Y16.25%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE Fundamental Analysis FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
What is the valuation status for AFX stock?
ChartMill assigns a valuation rating of 5 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
What is the profitability of AFX stock?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.
Can you provide the dividend sustainability for AFX stock?
The dividend rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 4 / 10 and the dividend payout ratio is 37.19%.